5d
Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout Agreement
Neurocrine’s rare-disease push, anchored by Soleno’s VYKAT XR, reshapes biotech dealmaking focus, today, April 6, 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results